considerations for apalutamide versus enzalutamide in prostate cancer treatment
Published 5 years ago • 532 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
8:09
comparing apalutamide and enzalutamide in real-world treatment of mcspc
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
1:31
spartan vs. prosper: apalutamide or enzalutamide for nmcrpc?
-
1:06
dr. bradley on adverse events associated with enzalutamide and apalutamide in prostate cancer
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
3:11
erleada or apalutamide adt treatment
-
12:42
pca commentary - nmcrpc and androgen receptor inhibition: enzalutamide, apalutamide and darolutamide
-
1:34
dr. chi on abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer
-
2:24
real-world psa responses to apalutamide or enzalutamide in mcspc
-
24:49
a journal article review enzalutamide in metastatic prostate cancer before chemotherapy
-
0:36
how is #apalutamide standard treatment beneficial to patients with node-positive prostate cancer?
-
0:35
"will adding apalutamide to my treatment improve my node-positive prostate cancer outcomes?"
-
6:13
clinical implications of new data on apalutamide adt in castrate-sensitive prostate cancer
-
2:17
enzalutamide for biochemically recurrent prostate cancer | nejm
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
13:18
recurrent prostate cancer,rising psa, apalutamide,abiraterone acetate,lupron,degarelix,enzalutamide
-
3:28
apalutamide and the titan clinical trial
-
5:20
apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer.
-
4:53
apalutamide: a next-gen agent for nonmetastatic crpc